Patients with previously diagnosed monogenic inflammatory diseases and non-immunologically determined phenotypes that were associated with type I IFN signaling were tested. Controls were selected from a diverse group without preexisting medical conditions. Samples from parents and siblings of patients with autosomal dominant interferonopathies who were themselves negative for the mutation were collected.